A drug for treating “breakthrough” cancer pain has been approved for UK use by the European Medicines Agency.
Introducing Nursing Times Learning
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Click on the topics below to get started:
Fentanyl pectin nasal spray (PecFent), manufactured by Archimedes Pharma, is indicated for treating breakthrough cancer pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain.
Episodes of breakthrough cancer pain are severe to excruciating in intensity, and occur in people who are already taking strong, opioid painkillers. Episodes can often reach maximum intensity within five minutes, and typically last 30-60 minutes.